Torigen, Inc.’s Post

🔍🐾 Early cancer detection just got a game-changer! Learn how the Onconeural High-Risk Antibody Test is transforming early diagnostics in pets, offering new hope for proactive care. Discover its impact on veterinary oncology in our latest blog! Pet Preferred Diagnostics, LLC https://lnkd.in/eJ5pzgEw #VetOncology #PetCancerCare #EarlyDiagnostics

Join us for "Bridging the Gap: What Oncologists Wish GPs Knew About Veterinary Oncology," sponsored by Pet Cancer Care Consulting. 🩺🐾 This insightful session is designed to help general practitioners better understand key aspects of oncology, from handling masses and diagnostic testing to staging and treatment options. 👨🏫 Learning Objectives: -Best practices for approaching masses -Updates on diagnostic testing to obtain accurate diagnoses -Staging cancer and its impact on treatment decisions -How GPs and oncologists can collaborate more effectively -What oncologists need before referral Don't miss this opportunity to improve your veterinary oncology knowledge and enhance GP-specialist collaboration! 👉 Register here: https://lnkd.in/eSaTe9Sp #VetOncology #VetCPD #PetCancerCare #TheWebinarVet #GPsAndSpecialists

I am thrilled to share that the article titled “Relative Tumour Volume in Canine Oral Melanoma Staging and Prognosis" has been published in Veterinary and Comparative Oncology journal! 🎉 In this retrospective study regarding Canine Oral Melanoma, we explored the staging and prognostic value of a tumor ratio instead of absolute tumor volume alone, since dogs have a vast phenotypic diversity.  This study was a result of a collaboration between the Faculties of Veterinary Medicine from University of Lisbon, in Portugal, and Universities of Parma and Torino, in Italy. I hope this study contributes to the ongoing conversation about how certain clinical variables can impact Canine Oral Melanoma prognosis and how we can manage them to better treat these patients. A huge thank you to all authors: Inês Martinho, Margarida Rocha, Marina Martano, Kevin P. Spindler, Paolo Buracco, Davide Giacobino, Helena Florindo and Lisa Mestrinho, for their invaluable work, collaboration and help throughout this journey! 💪 I invite you all to read it and share your thoughts! DOI: https://lnkd.in/dbR7AZd5 #Melanoma #Research #CanineCancer #VeterinaryMedicine

What is a pain point for you in clinics today? That’s a question Ethos is asking their clinics to advance medicine. Listen to learn more

🚨 Watch On-Demand: Transforming Canine Cancer Care Webinar! 🚨 Missed the live event? No problem! You can now watch the on-demand webinar sponsored by CanCan Diagnostics Ltd, "Transforming Canine Cancer Care: Early Relapse Detection and Disease Monitoring with Cutting-Edge Liquid Biopsy Technology." 🔍 What You’ll Learn: -Innovative liquid biopsy technology for canine cancer care -Early relapse detection techniques -Advanced methods for disease monitoring Enhance your knowledge and skills in veterinary oncology with this insightful session! 🎥 Watch Now via the link in the comments. #VeterinaryWebinar #CanineCancerCare #LiquidBiopsy #VetOncology #VeterinaryMedicine #OnDemandWebinar

FidoCure will present important new findings on canine hemangiosarcoma (HSA) at the 2024 Veterinary Cancer Society (VCS) Annual Conference, October 17-19 at the Caribe Royale Orlando! This marks our continued leadership in the largest and most prestigious conference in the veterinary oncology field. Canine splenic hemangiosarcoma, a particularly aggressive cancer that originates in the spleen, is responsible for approximately 300,000 dog deaths annually in the U.S. At the conference, Dr. Lucas Rodrigues, FidoCure's Head of Veterinary Research, will unveil our latest findings on HSA. The study demonstrates that AI-driven precision oncology for dogs with splenic hemangiosarcoma yields outcomes that are comparable to, or even exceed, those achieved with standard adjuvant chemotherapy. Furthermore, we have pinpointed specific genetic mutations that are closely linked to prognosis, significantly advancing our understanding of canine HSA. Visit us at Booth 25 to learn how our data-driven approach and innovative therapies are enhancing treatment outcomes and quality of life for dogs with cancer. Discover how we're elevating the standard of care in veterinary oncology and developing first-class precision therapies for canine cancer. Learn more about the research. https://bwnews.pr/4eLGQYR #VeterinaryOncology #CanineCancer #PrecisionMedicine #VCS2024 #VeterinaryCancerSociety #FidoCure #Hemangiosarcoma

🧬 Boost Your Oncology Knowledge! 🧬 Are you ready to refresh your understanding of oncology in veterinary practice? Our Oncology Refresher Course is here to help you stay up to date with the latest insights in diagnosing and managing cancer in animals. With expert-led webinars, you’ll gain valuable knowledge on cancer treatment, case management, and best practices for improving patient outcomes. 🐾 👉 Start learning today: https://lnkd.in/eVc8PX5Y Don't miss out on this opportunity to enhance your expertise! #VeterinaryOncology #VetLearning #OncologyRefresher #VeterinaryEducation #TheWebinarVet

The results have come back from the laboratory and confirmed the mass is malignant, as you suspected. Now you want to lay out all the possible options for the owner to decide what to do next. Would surgical resection alone be curative, or should you be advising chemotherapy, or both? What are the survival times on all of these options? If the owners choose to go down the route of palliative care, what would this likely look like? It’s a big decision, and there are often no right or wrong answers. ❤️ We can support you in practice, by offering an advice call with our oncology specialist to discuss case management and next steps. We even offer a specialist and owner teleconsultation in which the owners can attend alongside yourself if you would prefer. If you decide chemotherapy is the best option, then we can help with a protocol tailored to the individual patient, and can provide follow-up support too. Email us at info@vvs.vet for more details on getting support with oncology cases. www.vvs.vet #VVS #VirtualVeterinarySpecialists #VeterinaryPractice #VetSkills #VeterinarySurgeon #VeterinaryNurse #VeterinaryCare #AnimalHealth #Oncology #VeterinaryOncology #CaseStudies

A new paper in veterinary and comparative oncology highlights the high variability in patient size and how tumour “size” alone is a cumbersome prognostic metric. Instead, using tumour volume to body or weight ratios makes a lot more sense. In our preliminary study to develop an ML algorithm that can predict lymph node metastasis, this metric was not significantly correlated with traditional outcome measures, but we had a smaller sample size. This work from a team in Portugal is important and intriguing; highlighting the role for our automated tumour segmentation models in canine oral tumours. Stay tuned to learn more! Study Link: https://lnkd.in/ggznizNN

Two years ago, FidoCure® and Thrive Pet Healthcare joined forces to bring the patented FidoCure precision medicine platform to veterinarians across the Thrive network. Today, I'm proud to share the incredible impact of our partnership: • 400+ canine cancer cases treated in the initial phase • 25% year-over-year growth from the Thrive network • 5,000+ dogs treated with FidoCure's precision medicine platform But beyond the numbers, we’re seeing the ripple effect of our work. Through our patented novel approach and cutting-edge genomic sequencing, these canine cancer warriors are contributing to advancements in human cancer research. As we grow into our next phase of AI-driven drug development, we're not just fighting cancer in pets – we're crushing cancer on both sides of the leash. Here's to two years of lifesaving collaboration! Click below for the full story, featuring Venya, a 13½-year-old German Shepherd who inspires us to push the boundaries of veterinary oncology as she thrives despite multiple cancer diagnoses. https://hubs.li/Q02QC0840